NASDAQ: GALT - Galectin Therapeutics Inc.

Yield per half year: -49.56%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Galectin Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

more details
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2002-09-09
ISIN US3632252025
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://galectintherapeutics.com
Цена ао 2.37
Change price per day: +32.17% (0.8701)
Change price per week: +10.58% (1.04)
Change price per month: -59.44% (2.835)
Change price per 3 month: -57.56% (2.71)
Change price per half year: -49.56% (2.28)
Change price per year: -30.72% (1.66)
Change price per 3 year: -50.43% (2.32)
Change price per 5 year: -62.05% (3.03)
Change price per 10 year: 0% (1.15)
Change price per year to date: -61.67% (3)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -1.77 0
P/E 0 0
EV/EBITDA -4.01 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -145.62 0
ROE, % 68.17 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.89 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -98.47 0
Yield EPS, % 166.44 10
Total: 6
More

Institutions Volume Share, %
Vanguard Group Inc 1941854 3.14
Osaic Holdings Inc 1251048 2.02
Blackrock Inc. 715351 1.16
Geode Capital Management, LLC 514416 0.83
Geneos Wealth Management, Inc. 412650 0.67
Atria Wealth Solutions, Inc. 249800 0.4
Morgan Stanley 185147 0.3
Wealthspire Advisors, LLC 183862 0.3
State Street Corporation 161440 0.26
Cambridge Investment Research Advisors Inc. 126581 0.2

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.01442 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00247 38.04 0.6026
ProShares UltraPro Russell2000 0.00122 89.82 1.47873
ProShares Hedge Replication ETF 0.00034 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



Head Job title Payment Year of birth
Mr. Joel Lewis President, CEO & Director 907.72k 1970 (55 years)
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary 521.47k 1967 (58 years)
Robert Tritt General Counsel N/A
Mr. Jeff Katstra Head of CMC & Pharmaceutical Development N/A
Ms. Beth Knowles Executive Assistant & Officer Manager N/A
Mr. Khurram Jamil M.D. Chief Medical Officer

Address: United States, Norcross. GA, 4960 Peachtree Industrial Boulevard - open in Google maps, open in Yandex maps
Website: https://galectintherapeutics.com